| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000040666 |
| Receipt No. | R000046414 |
| Scientific Title | A preliminary test to examine the efficacy and safety of web-based brief intervention (ALMIGHT brief) for high-risk drinkers |
| Date of disclosure of the study information | 2020/06/08 |
| Last modified on | 2022/11/08 (Ver. 9) |
| Basic information | ||
| Public title | A preliminary test to examine the efficacy and safety of web-based brief intervention (ALMIGHT brief) for high-risk drinkers | |
| Acronym | A preliminary test to examine the efficacy and safety of web-based brief intervention (ALMIGHT brief) for high-risk drinkers | |
| Scientific Title | A preliminary test to examine the efficacy and safety of web-based brief intervention (ALMIGHT brief) for high-risk drinkers | |
| Scientific Title:Acronym | A preliminary test to examine the efficacy and safety of web-based brief intervention (ALMIGHT brief) for high-risk drinkers | |
| Region |
|
|
| Condition | ||
| Condition | Heavy drinker | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of this study is to examine the feasibility of ALMIGHT Brief and preliminarily consider the efficacy and safety of ALMIGHT Brief. ALMIGHT Brief is the 8-weeks-web-based brief counseling program based on cognitive-behavioral therapy for heavy drinkers to reduce the amounts of alcohol consumptions.
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Change in HDD(Heavy Drinking Day) repeatedly measured by TLFB which is provided during baseline(one time/week, three times in total) and during intervention(one time/week, 8 times in total).
HDD is calculated weekly. The calculation for HDD is that the number of days which the amount of alcohol consumption is higher than 61g per day in men, or 41g per day in women is divided by the number of days which the data of alcohol consumption is correctly obtained (not missed)and multiplied by 7. If the number of days which the data is correctly obtained (not missed)was less than 3 days per a week, all the datas of the week will be treated as missing datas. |
| Key secondary outcomes | - TAC(total alcohol consumption) repeatedly measured by TLFB which is provided during baseline(one time/week, three times in total) and during intervention(one time/week, 8 times in total)
The calculation for TAC is similar to that for HDD. Also, a missing data is defined in Primary outcome section. - Change in quality of life(AQolS) and productivity(HPQ) after the 8-weeks-intervention compared with the baseline period. - TLFB at 12 weeks and 24 weeks after the intervention. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Educational,Counseling,Training | |
| Type of intervention |
|
|
| Interventions/Control_1 | A 3-week baseline is used as a control, and an 8-week web-based brief counseling to reduce the amount of alcohol consumption is used as an intervention. | |
| Interventions/Control_2 | A 3-week baseline is used as a control, and an 8-week web-based brief counseling and an application(ver.1) to reduce the amount of alcohol consumption is used as an intervention. | |
| Interventions/Control_3 | A 3-week baseline is used as a control, and an web-based brief counseling and an application(ver.2) to reduce the amount of alcohol consumption is used as a intervention. | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Participants who speak Japanese and aged 20 and over
2) Participants with a high or very high DRL both at screening and at the start of the intervention. (DRL is assessed by the average daily alcohol intake. ) 3)Participants in employment 4)Participants who are able to receive online counseling via video call with a smartphone (5)Participants who can communicate with the clinical trial implementation staff (6)Participants who have a will to use the application for reducing alcohol consumption after receiving counseling via video call at a predetermined time and procedure (7)Participants who understand the purpose and content of this research and can give consents in writing to participate in the research voluntarily. |
|||
| Key exclusion criteria | (1) Those whose Heavy Drinking Days (Heavy Drinking Day: HDD, 61 + g/day in men and 41 + g/day in women) Is less than 6 in the 4 weeks prior to the screening
(2) Those who have five straight non-drinking days in the 4 weeks prior to the screening (3) Those who participated in an alcohol use disorder treatment or drinking reduction support program or self-help group in the four weeks prior to screening (4) Those who had received other structured psychotherapy in the four weeks prior to screening (5) Those with intellectual disability or dementia (DSM-5) (6) Those who used incompatible drugs in the 4 weeks prior to screening (7) Those with clinically serious and unstable complications. (8) Those who has had a history of alcohol withdrawal delirium or convulsive seizures due to alcohol withdrawal. (9) Those with a history of epilepsy or a history of seizures. (10) Those with significant rarefaction at the time of the screening or at the start of the intervention (11) Those who have been judged to be at serious suicide risk by the principal investigator or co-investigators (12) Those who drive vehicles with their main job, or who are engaged in hazardous occupations such as operating machinery or working at height (13) Those who participated in any clinical trial in the 4 weeks prior to the screening (14) Those who do not have a fixed address or telephone number (15) Those who do not routinely use a smartphone installed with iOS 13.0 or higher (16) Those who do not use the LINE messaging app on their smartphones (17) Those who has been judged to be not suitable for the subject of this this study by the principal investigator |
|||
| Target sample size | 15 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CureApp, Inc. | ||||||
| Division name | Medical Division Regulatory Affairs Department | ||||||
| Zip code | 103-0001 | ||||||
| Address | 12-5 Nihonbashi Kodenmacho YS Building 4F, Chuo-ku, Tokyo, Japan | ||||||
| TEL | 03-6231-0183 | ||||||
| ryuhei.so@cureapp.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CureApp, Inc. | ||||||
| Division name | Medical Division Clinical Development Department | ||||||
| Zip code | 103-0001 | ||||||
| Address | 12-5 Nihonbashi Kodenmacho YS Building 4F, Chuo-ku, Tokyo, Japan | ||||||
| TEL | 03-6231-0183 | ||||||
| Homepage URL | |||||||
| maki.miyazaki@cureapp.jp | |||||||
| Sponsor | |
| Institute | CureApp, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | CureApp, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | National Hospital Organization Kurihama medical and Addiction center |
| Address | 5-3-1, Nobi, Yokosuka city, kanagawa prefecture, Japan |
| Tel | 046-848-1550 |
| 220-shomuhanchou@mail.hosp.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 株式会社CureApp |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046414 |